Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau

Hyperphosphorylation of tau may contribute to epileptogenesis. Liu et al. reveal a reduction in the activity of protein phosphatase 2A (PP2A), with concomitant hyperphosphorylation of tau, in animal models of kindling, post-status epilepticus and post-traumatic epilepsy. Sodium selenate, a PP2A activator, prevents epileptogenesis in all three models.Hyperphosphorylation of tau may contribute to epileptogenesis. Liu et al. reveal a reduction in the activity of protein phosphatase 2A (PP2A), with concomitant hyperphosphorylation of tau, in animal models of kindling, post-status epilepticus and post-traumatic epilepsy. Sodium selenate, a PP2A activator, prevents epileptogenesis in all three models.There are no treatments in clinical practice known to mitigate the neurobiological processes that convert a healthy brain into an epileptic one, a phenomenon known as epileptogenesis. Downregulation of protein phosphatase 2A, a protein that causes the hyperphosphorylation of tau, is implicated in neurodegenerative diseases commonly associated with epilepsy, such as Alzheimer's disease and traumatic brain injury. Here we used the protein phosphatase 2A activator sodium selenate to investigate the role of protein phosphatase 2A in three different rat models of epileptogenesis: amygdala kindling, post-kainic acid status epilepticus, and post-traumatic epilepsy. Protein phosphatase 2A activity was decreased, and tau phosphorylation increased, in epileptogenic brain regions in all three models. Continuous sodium selenate treatment mitigated epileptogenesis and prevented the biochemical abnormalities, effects which persisted after drug withdrawal. Our studies indicate that limbic epileptogenesis is associated with downregulation of protein phosphatase 2A and the hyperphosphorylation of tau, and that targeting this mechanism with sodium selenate is a potential anti-epileptogenic therapy.